Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE 2nd, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD.

Neuro Oncol. 2008 Apr;10(2):182-9. doi: 10.1215/15228517-2007-053. Epub 2008 Feb 20.

2.

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS.

Clin Cancer Res. 2007 Feb 15;13(4):1253-9.

3.

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.

Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA.

J Neurooncol. 2007 May;83(1):53-60. Epub 2007 Jan 24.

PMID:
17245623
4.

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.

Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Smith C, Gong JZ, Lagoo A, Niedzwiecki D, Dowell JM, Waters-Pick B, Liu C, Marshall D, Vredenburgh JJ, Gockerman J, Decastro C, Moore J, Chao NJ.

J Clin Oncol. 2007 Feb 20;25(6):690-7. Epub 2007 Jan 16.

PMID:
17228020
5.

Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study.

Kornblith AB, Dowell JM, Herndon JE 2nd, Engelman BJ, Bauer-Wu S, Small EJ, Morrison VA, Atkins J, Cohen HJ, Holland JC.

Cancer. 2006 Dec 1;107(11):2706-14.

6.

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.

Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, Gururangan S, Wong TZ, Badruddoja MA, Zhao XG, Bigner DD, Zalutsky MR.

J Nucl Med. 2006 Jun;47(6):912-8.

7.

Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.

Kuan CT, Wakiya K, Dowell JM, Herndon JE 2nd, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1970-82.

8.

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE 2nd, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, Lyons P, Tourt-Uhlig S, Bigner DD, Friedman HS, Rich JN.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):860-8.

9.

Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001.

Redston M, Compton CC, Miedema BW, Niedzwiecki D, Dowell JM, Jewell SD, Fleshman JM, Bem J, Mayer RJ, Bertagnolli MM; Leukemia Group B Trial 80001.

J Clin Oncol. 2006 Feb 20;24(6):878-83. Epub 2006 Jan 17.

PMID:
16418493
10.

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD.

J Clin Oncol. 2006 Jan 1;24(1):115-22. Erratum in: J Clin Oncol. 2006 Mar 20;24(9):1484. Guruangan, Sri [corrected to Gururangan, Sridharan].

PMID:
16382120
11.

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS.

J Clin Oncol. 2005 Dec 20;23(36):9359-68. Erratum in: J Clin Oncol. 2006 Mar 1;24(7):1224. Rich, Jeremy N Sr [corrected to Rich, Jeremy N]; Gururangan, Idharan [corrected to Gururangan, Sridharan].

PMID:
16361636
12.

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.

Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, Sathornsumetee S, Badruddoja M, McLendon R, Provenzale J, Herndon JE 2nd, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS.

Cancer. 2005 Oct 1;104(7):1478-86.

13.

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.

Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE 2nd, Dowell JM, Friedman AH, Friedman HS.

Cancer. 2005 Jan 15;103(2):329-38.

14.

Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers.

Goel A, Arnold CN, Tassone P, Chang DK, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR.

Int J Cancer. 2004 Dec 10;112(5):754-9.

15.

APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q.

Arnold CN, Goel A, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR.

Cancer Biol Ther. 2004 Oct;3(10):960-4. Epub 2004 Oct 27.

PMID:
15326380
16.

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.

Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE 2nd, Dowell JM, Affronti ML, Jackson S, Allen D, Ziegler K, Silverman S, Bohlin C, Friedman AH, Bigner DD, Friedman HS.

Neuro Oncol. 2004 Apr;6(2):134-44.

17.

Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers.

Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR.

Cancer Res. 2004 May 1;64(9):3014-21.

18.

Cost comparison of radical retropubic and radical perineal prostatectomy: single institution experience.

Silverstein AD, Weizer AZ, Dowell JM, Auge BK, Paulson DF, Dahm P.

Urology. 2004 Apr;63(4):746-50.

PMID:
15072893
19.

Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer.

Arnold CN, Goel A, Compton C, Marcus V, Niedzwiecki D, Dowell JM, Wasserman L, Inoue T, Mayer RJ, Bertagnolli MM, Boland CR.

Cancer Biol Ther. 2004 Jan;3(1):73-8. Epub 2004 Jan 5.

PMID:
14726676
20.

Phase II trial of gefitinib in recurrent glioblastoma.

Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS.

J Clin Oncol. 2004 Jan 1;22(1):133-42. Epub 2003 Nov 24.

PMID:
14638850
21.

Characterization of sporadic colon cancer by patterns of genomic instability.

Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR.

Cancer Res. 2003 Apr 1;63(7):1608-14.

Supplemental Content

Loading ...
Support Center